Eyevensys
Platforms for long acting non-viral gene therapy for ocular diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
€136m (Public information from Aug 2021)
Company register number 509397832
Paris Île-de-France (HQ)
Financials
Estimates*
EUR | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|---|---|---|
EBITDA | (2.9m) | (2.2m) | (3.4m) | (5.5m) | - | (6.1m) | (10.8m) |
Profit | (1.8m) | (1.8m) | (2.6m) | (4.9m) | (7.8m) | (4.7m) | (9.5m) |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
* | N/A | Spinout | |
N/A | Early VC | ||
N/A | Seed | ||
* | €9.0m | Series A | |
$30.0m | Series B | ||
$12.0m Valuation: $150m -22.3x EV/LTM EBITDA | Series B | ||
Total Funding | €47.2m |
Recent News about Eyevensys
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.